<?xml version="1.0" encoding="UTF-8"?>
<ref id="B3-pharmaceutics-12-00388">
 <label>3.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bliss</surname>
    <given-names>C.M.</given-names>
   </name>
   <name>
    <surname>Bowyer</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Anagnostou</surname>
    <given-names>N.A.</given-names>
   </name>
   <name>
    <surname>Havelock</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Snudden</surname>
    <given-names>C.M.</given-names>
   </name>
   <name>
    <surname>Davies</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>De Cassan</surname>
    <given-names>S.C.</given-names>
   </name>
   <name>
    <surname>Grobbelaar</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Lawrie</surname>
    <given-names>A.M.</given-names>
   </name>
   <name>
    <surname>Venkatraman</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP</article-title>
  <source>Sci. Rep.</source>
  <year>2018</year>
  <volume>8</volume>
  <fpage>3390</fpage>
  <pub-id pub-id-type="doi">10.1038/s41598-018-21630-4</pub-id>
  <pub-id pub-id-type="pmid">29467399</pub-id>
 </element-citation>
</ref>
